Texas cannabis policy is moving in two directions at the same time. The state is expanding its tightly controlled medical program, adding licenses, satellite dispensing locations, qualifying conditions, and dosage forms. At the same time, regulators are applying stricter total-THC rules to the much larger retail hemp market, and a long-running lawsuit is still affecting when some restrictions can be enforced.
A product sold by a registered medical dispensing organization is governed by the Texas Compassionate Use Program. A gummy, flower jar, vape, or drink sold by a hemp retailer falls under a different statute, regulator, license, and testing system. Expansion of one channel does not make a product in the other channel legal.
Texas Still Has Two Cannabis Systems
The medical side begins with a participating physician and the Compassionate Use Registry of Texas, commonly called CURT. Texas does not use the familiar plastic “medical marijuana card” model found in many other states. A physician determines whether an eligible patient may benefit, enters a prescription in the registry, and a licensed dispensing organization verifies the patient before dispensing.
The retail hemp side grew from the state’s 2019 hemp law. It created a commercial route for consumable hemp products that met the statutory definition of hemp. Stores multiplied, product chemistry changed quickly, and intoxicating products made from or marketed as hemp became widely available without a CURT prescription. That market never became part of the medical program, even when a shopper used a product for pain, sleep, anxiety, or another health concern.
That distinction matters now because a stricter rule for retail hemp does not automatically change what a registered medical patient can obtain from a licensed dispensary. The reverse is also true: a broader medical program does not shield a smoke shop, manufacturer, or online hemp seller from DSHS rules.
What Changed in the Medical Program
House Bill 46 took effect September 1, 2025. According to the Texas Department of Public Safety, it requires the agency to bring the program to 15 dispensing-organization licenses. Texas had three active licenses when DPS published its summary, leaving 12 additional licenses to be issued. More licensees can increase competition and geographic reach, although a license award does not instantly create a fully operating dispensary.
The law also permits satellite locations within public-health regions in addition to a licensee’s primary location. That change addresses one of the program’s most persistent problems: Texas is enormous, but licensed medical access has historically depended on a small number of organizations and a patchwork of pickup and delivery arrangements.
DPS also says the legislation expanded qualifying conditions and the dosage forms available through the program. Patients should still confirm the current eligibility list with DPS and discuss treatment with a participating physician. A broader statute is not a promise that a particular patient will qualify, that a specific formulation is appropriate, or that every new location is already open.
Why Hemp Products Face Tighter Scrutiny
On the hemp side, the Texas Department of State Health Services adopted long-term rules on March 31, 2026 after an executive order directed the agency to address age verification, testing, labels, fees, records, and enforcement coordination. In a July presentation to state senators, DSHS said it was enforcing age-gating, including THCA in the total delta-9 amount, new labeling requirements, and updated fees.
The move to total THC is consequential. THCA is not merely a different set of letters on a label; it can convert to delta-9 THC when heated. A flower or concentrate that appears to satisfy a delta-9-only number may fail a total-THC calculation. That is why a package’s front-panel claim is not enough. Retailers need compliant batch records, and consumers need a certificate of analysis tied to the exact lot.
DSHS also reported rapid market growth. As of June 18, 2026, its presentation counted 10,853 consumable-hemp retailers and 14,170 retail locations. Those figures explain the stakes: this is not a small regulatory adjustment affecting a handful of specialty stores. The rules touch a statewide network of manufacturers, convenience retailers, dedicated hemp shops, employees, landlords, laboratories, and customers.
The Smokeable-Hemp Fight Is Not a Clean Deadline
Recent reporting has focused on a July 31 deadline for smokeable products containing delta-8 and other intoxicating cannabinoids. That deadline should not be read without the court docket. The Sky Marketing litigation has moved through multiple courts, and new orders have changed the practical status of the rules on short notice. A product that appeared headed off shelves could be temporarily protected again by an injunction or stay.
For that reason, CannaWize will not describe the outcome as settled while appellate proceedings remain active. Retailers should rely on current written guidance from DSHS, their counsel, and the latest court order—not a screenshot of an older headline. Consumers should expect inventory changes and should not assume that a product displayed for sale has been reviewed or approved by the state.
What Patients and Shoppers Should Verify
- Which channel is this? A CURT dispensing organization and a registered hemp retailer operate under different rules.
- Who regulates it? DPS administers the medical program; DSHS administers the Consumable Hemp Program.
- What does the batch report show? Match the lot number and review total THC, contaminants, laboratory identity, and testing date.
- Is the legal information current? Check the date, agency notice, and court status before making an inventory, travel, or purchase decision.
- Is a health claim doing the selling? A retail label or salesperson cannot diagnose a condition or substitute for a clinician.
The Policy Split Is the Story
Texas is not moving smoothly from prohibition to one regulated adult cannabis market. It is strengthening a physician-supervised medical channel while attempting to restrict an expansive hemp market that developed outside that channel. Supporters of the medical expansion see better access and oversight. Hemp businesses argue that abrupt restrictions can eliminate lawful products and established companies. Public-health advocates point to inconsistent labels, youth access, and intoxicating products sold with fewer controls than medical cannabis.
Those arguments will continue in agencies, courts, and the Legislature. For readers, the practical rule is simpler: identify the legal channel before judging the product. “Cannabis,” “hemp,” “THCA,” and “medical” may appear together in marketing, but Texas law assigns them very different consequences.